Kura Oncology, Inc. KURA
- KOMZIFTI — Acute Myeloid Leukemia Approved
- KOMZIFTI — Pediatric Acute Leukemia Phase 1
- KOMZIFTI — Gastrointestinal Stromal Tumor Phase 1
KMT2A (2 companies · 4 programs)
Companies with an active program directed at KMT2A.
Syndax Pharmaceuticals Inc SNDX
- Revuforj — Relapsed/Refractory Acute Leukemia with KMT2A Translocation Approved